Business Standard
Sunday, Nov 08, 2009
 
drived banner
drived banner
  Advanced Search
Feedback | RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Smart Portfolios II
  Search:

Sun Pharma gets USFDA nod for four generic drugs
Press Trust of India / New Delhi January 07, 2009, 21:12 IST

Drug major Sun Pharmaceutical Industries today said the company, along with its subsidiary, has received abbreviated new drug application (ANDA) approval for four generic products from the US health regulator.

 
 
News Now
Paper
Specials
- Hat-trick of gains
- Wkly Tech Analysis: Nifty may move in 4,640-4,900 band
- Chandrayaan-II mission to be completed by 2012-13: Annadurai
- Faheem Ansari seeks re-trial of 26/11 case
- US faces potential minefield over Muslims and military
More  

The company has received approvals from the US Food and Drug Administrator (USFDA) for generic hydrocodone bitarlate with acetaminophen (APAP) tablets, generic Aredia Pamidronate Disodium injections, generic Lopid gemfibrozil tablets and generic Phenargan promethazine hydrochloride tablets in various strengths, Sun Pharma said in a statement.

These products -- both generic and branded verions -- all together have annualised sales of more than $650 million in the US.

The company has received the approval for 10 generic versions of Hydrocodone with APAP used as pain reliever for acute, chronic and post operative pains, it added.

While Lopid tablets are used as cholesterol reducing agents and generic Aredia injections can treat hypercalcemia, Phenargan tablets are pain relievers, the company said.

All these products are manufactured at multiple facilities of the company and its subsidiaries in the US and India.

  Read Business news in 
  Your dream home can now be a reality.
  Visit Fortis for a preventive health check-up & get a 20% discount.
  Follow the ups and downs of your investments. Try our new Portfolio Tracker
  Kolkata Dock \ Freight contract for the British Gurkhas Nepal
  Find how Midsize Businesses use ERP to gain competitive advantage
  Trading in Forex is now as easy as 1-2-3
  Discover an economical and cost effective way to market your products and services
  Giftwithlove.com: Same day delivery of Flowers and Cakes to India
  Download the E-book on the Future of Business Intelligence
  Learn Best Practices for improving customer satisfaction
  Know your customers better... download the free e-book on CRM
   Discussion Board / User Comments    
Display Name  Email-Id  
Post your comment
Most Popular
Read
E-Mailed
Commented
   
- Vendors to share BSNL's 3G ad spend
- Great Indian telecom boom begins to ring hollow
- Profit booking seen next week
- DTH sparks new row between producers and multiplexes
- Now, shell out Rs 80,000 more for a designer Nano
 
 More  
BS Poll
Cast Your Vote
 
   
 
Should the private sector be allowed to manage urban water supply?
  Yes  No
Submit

  Hot Searches  
 
Amitabh Bachchan | N Chandrasekaran | Swine Flu | Mukesh Ambani | Anil Ambani | TCS | Infosys |  Air India |  Duronto |  Pranab Mukherjee | Sonia Gandhi | Congress | Rahul Gandhi |  Bigg Boss |  New Pension Scheme |  Service tax |  Excise duty |  Sebi | Tech Mahindra |  Ramalinga Raju |  Satyam |  Reliance  |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  |  B-School | DLF  Sensex |  Tax calculator | Home Loan  | Bollywood | Personal Finance |  inflation | oil prices |  World Bank | Reliance Infratel |  HDFC |  Barack Obama  
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Site Map | Contact Us | Feedback